Matthew Plunkett, EVP, Chief Business Officer at CTI BIOPHARMA CORP (CTIC), sold 18,600 shares at $0.58 ($11K) on 2016-03-04, disclosed to the SEC on 2016-03-04.
Seasonal sale ($11k) by EVP, Chief Business Officer — this insider has traded CTIC in March in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.58 | 1,300 | $761 | 6.9% |
| 2 | $0.59 | 400 | $234 | 2.1% |
| 3 | $0.59 | 636 | $373 | 3.4% |
| 4 | $0.59 | 1,500 | $882 | 8.0% |
| 5 | $0.59 | 844 | $497 | 4.5% |
| 6 | $0.59 | 1,500 |
| $885 |
| 8.0% |
| 7 | $0.59 | 400 | $236 | 2.1% |
| 8 | $0.59 | 500 | $295 | 2.7% |
| 9 | $0.59 | 636 | $375 | 3.4% |
| 10 | $0.59 | 700 | $413 | 3.8% |
| 11 | $0.59 | 844 | $498 | 4.5% |
| 12 | $0.59 | 1,100 | $649 | 5.9% |
| 13 | $0.59 | 1,300 | $767 | 7.0% |
| 14 | $0.59 | 200 | $118 | 1.1% |
| 15 | $0.59 | 700 | $414 | 3.8% |
| 16 | $0.59 | 200 | $118 | 1.1% |
| 17 | $0.59 | 1,100 | $652 | 5.9% |
| 18 | $0.59 | 500 | $297 | 2.7% |
| 19 | $0.59 | 1,220 | $726 | 6.6% |
| 20 | $0.60 | 900 | $536 | 4.9% |
| 21 | $0.60 | 1,220 | $732 | 6.7% |
| 22 | $0.60 | 900 | $540 | 4.9% |
| Total | $0.59 avg | 18,600 | $11K | 100% |
| Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |
| CTIC | SELL | 2015-10-07 | $15K | — | Filing → |